6533b835fe1ef96bd129ea76
RESEARCH PRODUCT
Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study.
Verena LiebMartin DrerupJohannes BruendlFabian SiegelAngelika BorkowetzTobias B JordanJost Von HardenbergKira KornienkoHannes CashKasra TaymoorianThomas HöfnerManuela A HoffmannRoman GanzerMartin SchostakNiklas Westhoffsubject
Malemedicine.medical_specialtyProstate biopsyUrologyBiopsy030232 urology & nephrologyCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineProstateBiopsyMedicineHumansmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsMagnetic resonance imagingProstate-Specific Antigenmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structure030220 oncology & carcinogenesisProstate neoplasmRadiologybusinessEnergy sourceCohort studydescription
Focal therapy (FT) with its favorable side-effect profile represents an option between active surveillance and traditional whole-gland treatment in localized prostate cancer (PCa). Consensus statements recommend eligibility criteria based on magnetic resonance imaging (MRI)-targeted and systematic combination biopsy.To estimate the future potential of FT by analyzing the number of men eligible for FT among all men with biopsy-proven PCa and to judge the potential of different energy sources.Consensus criteria on FT were analyzed. Patients with biopsy-proven PCa from six tertiary referral hospitals and one outpatient practice in Germany had received a software-based combination biopsy. Men with Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesions based on PI-RADS v2 were included.Patients were analyzed for potential treatment by FT and hemiablation. MRI lesions were mapped according to prostatic zones.In total, 2371 patients were analyzed. According to consensus criteria (biopsy-proven unifocal lesion of International Society of Urological Pathology [ISUP] grade group ≤2, prostate-specific antigen [PSA] ≤15ng/mL, and life expectancy10yr), 303 patients (12.8%; ISUP 1: n=148 [6.2%]; ISUP 2: n=155 [6.5%]) were potential candidates for FT. A maximum PSA level of10ng/mL would exclude further 60 (2.5%) of these men. The eligibility for hemiablation is slightly higher (16.2%). Unifocal lesions (n=288) were equally distributed within the prostate (anteriorly [31%], apically [29%], and dorsally [36%]).With adherence to consensus statements, only a minority of PCa patients present as potential candidates for FT. Distribution of tumor localization suggests the need for different energy modalities to warrant an optimal FT treatment.We analyzed how many men who receive a magnetic resonance imaging-targeted and systematic prostate biopsy are candidates for the experimental focal therapy of the prostate. When following expert recommendations, only a small number of men are potential candidates for this alternative treatment.
year | journal | country | edition | language |
---|---|---|---|---|
2020-07-04 | European urology focus |